Tarsus Pharmaceuticals (TARS) Competitors

Lantheus (NASDAQ:LNTH) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Do insiders and institutionals believe in LNTH or TARS?

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 1.5% of Lantheus shares are owned by insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the media prefer LNTH or TARS?

In the previous week, Tarsus Pharmaceuticals had 11 more articles in the media than Lantheus. MarketBeat recorded 22 mentions for Tarsus Pharmaceuticals and 11 mentions for Lantheus. Lantheus' average media sentiment score of 1.27 beat Tarsus Pharmaceuticals' score of 1.17 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	13 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is LNTH or TARS more profitable?

Lantheus has a net margin of 28.57% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Lantheus' return on equity of 44.29% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	28.57%	44.29%	23.52%
Tarsus Pharmaceuticals	-103.64%	-55.86%	-39.28%

Which has stronger valuation & earnings, LNTH or TARS?

Lantheus has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.53B	4.85	$326.66M	$4.37	24.88
Tarsus Pharmaceuticals	$182.95M	9.93	-$135.89M	-$3.10	-15.28

Does the MarketBeat Community prefer LNTH or TARS?

Lantheus received 289 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. However, 68.83% of users gave Tarsus Pharmaceuticals an outperform vote while only 66.02% of users gave Lantheus an outperform vote.

Company	Underperform	Outperform
Lantheus	Outperform Votes 342 66.02%	Underperform Votes 176 33.98%
Tarsus Pharmaceuticals	Outperform Votes 53 68.83%	Underperform Votes 24 31.17%

Which has more risk and volatility, LNTH or TARS?

Lantheus has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Do analysts rate LNTH or TARS?

Lantheus presently has a consensus target price of $134.33, suggesting a potential upside of 23.54%. Tarsus Pharmaceuticals has a consensus target price of $64.67, suggesting a potential upside of 36.54%. Given Tarsus Pharmaceuticals' higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tarsus Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Lantheus beats Tarsus Pharmaceuticals on 11 of the 18 factors compared between the two stocks.